Patients with chronic lymphocytic leukemia (CLL) have a sizable 600% higher risk of melanoma, the most dangerous form of skin cancer, a Wilmot Cancer Institute scientific team found out.
Although a higher risk of melanoma had been known, a full analysis of detection rates and treatments among CLL patients has never been reported before, said Clive Zent, Managing Director, who led the Wilmot Cancer Institute scientific team.
As a result of this new data, Zent, an international expert in CLL, recommends that all clinical teams who care for CLL patients should actively monitor for melanoma as a part of routine care. The goal is to catch the skin cancer early and manage it with the newest targeted therapies.
“We do not for sure know why CLL patients are more susceptible to melanoma, but the most likely cause is a suppressed immune system,” said Zent, a professor of Hematology and Oncology and Medicine at the University of Rochester Medical Cancer and Wilmot. “Normally, in people with healthy immune systems, malignant skin cells might be detected and destroyed before they become a problem. But in CLL patients, failure of this control system increases the rate at which cancer cells can grow into tumors, and also the likelihood that they will become invasive or spread to distant sites.”
Study results showed that 22 melanomas were diagnosed among 470 people in the cohort, a rate that’s more than 600% higher than what would be expected in a similar group of age- and gender-matched people from the general population. Of the 22 diagnoses, 15 (or 68%) were detected through monitoring in the UR Medicine dermatology clinic associated with Wilmot, and two cases (9%) were found by CLL specialists. 80% of the cases involved earlier-stage disease with a better prognosis, the study said.
CLL is the most common type of leukemia in the U.S., with about 140,000 people living with the disease. Immune dysfunction is a major complication. The study appears in the Leukemia Research journal.
Follow @htlifeandstyle for more
First Published: Aug 10, 2018 10:50 IST